The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis
Abstract
Abstract Rationale In October 2014, the antifibrotic medications pirfenidone and nintedanib became the first medications approved by the U.S. Food and Drug Administration for use in patients with idiopathic pulmonary fibrosis (IPF). Since approval, there has been no nonregistry analysis of the real-world adoption of these medications in everyday clinical practice. Objectives To evaluate the adoption, persistence, and out-of-pocket (OOP) costs of pirfenidone and nintedanib since their approval in the United States in 2014. Methods A retrospective cohort analysis was performed by identifying privately insured and Medicare Advantage beneficiaries with IPF. We then split the patients into three cohorts: those who were untreated and those who filled a prescription for either pirfenidone or nintedanib between October 1, 2014, and July 31, 2019. The primary outcome was adoption of the medications. Secondary outcomes included medication persistence and prescription drug costs. Results A total of 10,996 patients with IPF were identified in the data set. A minority of patients (26.4%) with IPF identified in the cohort had started either medication since approval in 2014, with the adoption of both medications being comparable at around 13.2%. Those receiving the medications were younger (72 vs. 73.9 yr; P < 0.0001) and healthier (3.9 vs. 4.9 comorbidities; P < 0.0001) than those not receiving treatment. Men were significantly more likely to receive treatment than woman (30.0% vs. 21.9%; P < 0.0001). Among treated patients, 42.8% discontinued the medications during the study period. Patients’ OOP expenses per month were high for both drugs (mean, $397.51 for nintedanib; mean, $394.49 for pirfenidone). Conclusions The adoption of both the antifibrotic medications in the United States in everyday practice has been low since approval and may be associated with the high OOP cost.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Their limited efficacy, combined with tolerability challenges, contributes to low treatment uptake, frequent discontinuation of both treatments, and impaired quality of life.6-8”
From Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial (2026) · cites this paper as [7]
Citations
Cites
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Medication compliance and persistence: terminology and definitions
Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00213.x · Cited by 2,220
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Prednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113354 · Cited by 1,654
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310
Idiopathic Interstitial Pneumonia
Flaherty, K. R., King, T. E., Raghu, G., Lynch, J. P., Colby, T. V., Travis, W. D., Gross, B. H., Kazerooni, E. A., Toews, G. B., Long, Q., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200402-147oc · Cited by 672
Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial
Raghu, G., Behr, J., Brown, K. K., Egan, J. J., Kawut, S. M., Flaherty, K. R., Martinez, F. J., Nathan, S. D., Wells, A. U., Collard, H. R., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-9-201305070-00003 · Cited by 553
King, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Incidence, Prevalence, and Clinical Course of Idiopathic Pulmonary Fibrosis
Pérez, E. R. F., Daniels, C. E., Sauver, J. L. S., Hartman, T. E., Bartholmai, B. J., Yi, E. S., Ryu, J. H., & Schroeder, D. R. (2009) · CHEST Journal · doi:10.1378/chest.09-1002 · Cited by 508
Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401739 · Cited by 506
A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
Noth, I., Anstrom, K. J., Calvert, S. B., de Andrade, J., Flaherty, K. R., Glazer, C., Kaner, R. J., & Olman, M. A. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201202-0314oc · Cited by 463
Walsh, S. L. F., Wells, A. U., Desai, S. R., Poletti, V. E., Piciucchi, S., Dubini, A., Nunès, H., Valeyre, D., Brillet, P., Kambouchner, M., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30033-9 · Cited by 461
Optum Labs: Building A Novel Node In The Learning Health Care System
Wallace, P. J., Shah, N. D., Dennen, T., Bleicher, P. A., & Crown, W. H. (2014) · Health Affairs · doi:10.1377/hlthaff.2014.0038 · Cited by 449
Self-citationIncidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old
Raghu, G., Chen, S., Hou, Q., Yeh, W., & Collard, H. R. (2016) · European Respiratory Journal · doi:10.1183/13993003.01653-2015 · Cited by 348
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial
Vancheri, C., Kreuter, M., Richeldi, L., Ryerson, C. J., Valeyre, D., Grutters, J. C., Wiebe, S., Stansen, W., Quaresma, M., Stowasser, S., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1301oc · Cited by 305
Burden of illness in idiopathic pulmonary fibrosis
Collard, H. R., Ward, A., Lanes, S., Hayflinger, D. C., Rosenberg, D., & Hunsche, E. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.680553 · Cited by 207
Raghu, G., & Selman, M. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201411-2044ed · Cited by 183
Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis
Dempsey, T. M., Sangaralingham, L. R., Yao, X., Sanghavi, D. M., Shah, N. D., & LIMPER, A. H. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201902-0456oc · Cited by 163
Self-citationSafety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
Flaherty, K. R., Fell, C. D., Huggins, J. T., Nunes, H., Sussman, R., Valenzuela, C., Petzinger, U., Stauffer, J. L., Gilberg, F., Bengus, M., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00230-2018 · Cited by 141
Cottin, V., & Maher, T. M. (2015) · European Respiratory Review · doi:10.1183/09059180.00011514 · Cited by 129
Sex differences in physiological progression of idiopathic pulmonary fibrosis
Han, M. K., Murray, S., Fell, C. D., Flaherty, K. R., Toews, G. B., Myers, J., Colby, T. V., Travis, W. D., Kazerooni, E. A., Gross, B. H., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00165207 · Cited by 128
Collard, H. R., Chen, S., Yeh, W., Li, Q., Lee, Y.-C., Wang, A., & Raghu, G. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201412-553oc · Cited by 115
Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 Inhibitors
Fischer, M. A., Schneeweiß, S., Avorn, J., & Solomon, D. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmsa042770 · Cited by 111
A New Hope for Idiopathic Pulmonary Fibrosis
Hunninghake, G. M. (2014) · New England Journal of Medicine · doi:10.1056/nejme1403448 · Cited by 57
Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
Salisbury, M. L., Conoscenti, C., Culver, D. A., Yow, E. S., Neely, M. L., Bender, S. D., Hartmann, N., Palmer, S. M., & Leonard, T. B. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201912-880oc · Cited by 55
Gender influences health-related Quality of Life in IPF
Han, M. K., Swigris, J. J., Liu, L., Bartholmai, B. J., Murray, S., Giardino, N. D., Thompson, B., Frederick, M., Li, D., Schwarz, M. I., et al. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.11.019 · Cited by 52
Self-citationPatient gender bias on the diagnosis of idiopathic pulmonary fibrosis
Assayag, D., Morisset, J., Johannson, K. A., Wells, A. U., & Walsh, S. L. F. (2020) · Thorax · doi:10.1136/thoraxjnl-2019-213968 · Cited by 52
Holtze, C. H., Freiheit, E., Limb, S. L., Stauffer, J. L., Raimundo, K., Pan, W. T., Flaherty, K. R., & Kim, H. J. (2020) · Respiratory Research · doi:10.1186/s12931-020-1315-4 · Cited by 50
King, C. S., & Nathan, S. D. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.04.034 · Cited by 18
Clarifying the diagnosis of post-inflammatory pulmonary fibrosis: a population-based study
Vu, A. N., Vasireddy, A., Moua, T., Baqir, M., & Ryu, J. H. (2019) · European Respiratory Journal · doi:10.1183/13993003.00103-2019 · Cited by 15
Culver, D. C., Yow, E. S., Neely, M. L., Belperio, J. A., Bender, S. D., de Andrade, J. A., Roman, J., Whelan, T. J., Palmer, S. M., & Conoscenti, C. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.08.366 · Cited by 13
Flagged first, then by citations
Research works printed but not linked: 4
- Flaherty, 2018, Baseline characteristics of 1461 participants in the pulmonary fibrosis foundation patient registry [abstract], Eur Respir J, 52, PA2199
- Wong, 2018, Direct oral anticoagulant prescription trends, switching patterns, and adherence in Texas Medicaid, Am J Manag Care, 24, SP309
- Achaiah, 2017, Tolerability and efficacy of pirfenidone and nintedanib for patients with IPF in real world clinical practice [abstract], Eur Respir J, 50, PA4879
- Eaddy, 2012, How patient cost-sharing trends affect adherence and outcomes: a literature review, P&T, 37, 45
Cited by
Sorted by citations
Idiopathic pulmonary fibrosis: Current and future treatment
Glass, D. S., Grossfeld, D. J., Renna, H. A., Agarwala, P., Spiegler, P. A., DeLeon, J. R., & Reiss, A. B. (2022) · The Clinical Respiratory Journal · doi:10.1111/crj.13466 · Cited by 322
Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
Chianese, M. I., Screm, G., Salton, F., Confalonieri, P., Trotta, L., Barbieri, M., Ruggero, L., Mari, M., Reccardini, N., Geri, P., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17060709 · Cited by 113
Sex and gender in interstitial lung diseases
Kawano-Dourado, L. B., Glassberg, M. K., Assayag, D., Borie, R., & Johannson, K. A. (2021) · European Respiratory Review · doi:10.1183/16000617.0105-2021 · Cited by 67
Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatment
Herberts, M. B., Teague, T., Thao, V., Sangaralingham, L. R., Henk, H. J., Hovde, K. T., Dempsey, T. M., & LIMPER, A. H. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02565-7 · Cited by 47
Self-citationShi, X., Chen, Y., Shi, M., Gao, F., Huang, L., Wang, W. J., Wei, D., Shi, C., Yu, Y., Xia, X., et al. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02062-8 · Cited by 44
Metadata
- Authors
- Dempsey, T. M., Payne, S., Sangaralingham, L., Yao, X., Shah, N. D., & Limper, A. H.
- Affiliations
- Department of Pulmonary and Critical Care Medicine
- Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery
- Mayo Clinic (US)
- Corresponding author
- Dempsey, Timothy M.
- ORCID
- Venue
- Annals of the American Thoracic Society
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-07-01
- Volume
- 18
- Issue
- 7
- Pages
- 1121-1128
- ISSN
- 2325-6621 (ISSN-L)
- 2329-6933
- OpenAlex
- W3122584685
- Cited by
- 101
- References
- 33
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 22 · 2023: 14 · 2022: 11 · 2021: 9
- FWCI
- 9.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of the American Thoracic Society (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- idiopathic pulmonary fibrosis, pirfenidone, nintedanib, antifibrotic agents, treatment persistence, out-of-pocket costs, prescription drug costs, Medicare Advantage beneficiaries, real-world applications, drug approval
- MeSH terms
- Aged, Pharmaceutical Preparations, Female, Medicare, Humans, Indoles, Male, Pyridones, Retrospective Studies, United States, Treatment Outcome, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
